Not applicableStudy completedNCT03718117What this trial is testingDescriptive Observational Study ALK-2016-CPHGWho this might be right forNSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement Pfizer 73
Not applicableUnknownNCT04921553What this trial is testingReal Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)Who this might be right forCancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more Centre Leon Berard 500
Testing effectiveness (Phase 2)UnknownNCT01964157What this trial is testingAn Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementWho this might be right forNon-small Cell Lung Cancer (NSCLC) Yonsei University 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772What this trial is testingPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Who this might be right forNon-Small Cell Lung Cancer AstraZeneca 247
Testing effectiveness (Phase 2)UnknownNCT04292119What this trial is testingLorlatinib Combinations in Lung CancerWho this might be right forLung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT05118789What this trial is testingZidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)Who this might be right forLocally Advanced Solid TumorMetastatic Solid Tumor Nuvalent Inc. 359
Testing effectiveness (Phase 2)UnknownNCT04989322What this trial is testingPembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCWho this might be right forNsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more Dr Joanne CHIU 46
Testing effectiveness (Phase 2)UnknownNCT03399487What this trial is testingLDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementWho this might be right forNon-small Cell Lung Cancer Harboring ROS1 Rearrangement Yonsei University 46
Early research (Phase 1)Ended earlyNCT04005144What this trial is testingBrigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerWho this might be right forALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more University of California, San Francisco 3
Not applicableNot Yet RecruitingNCT06694129What this trial is testingReal-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCWho this might be right forNon-Small Cell Lung CancerROS1 Gene RearrangementResistance+1 more National Cancer Center, China 40
Not applicableNo Longer AvailableNCT02473497What this trial is testingCrizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric PatientsWho this might be right forNeoplasm Pfizer
Not applicableStudy completedNCT03727477What this trial is testingEfficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving LorlatinibWho this might be right forNon-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive Intergroupe Francophone de Cancerologie Thoracique 291
Early research (Phase 1)Study completedNCT05055232What this trial is testingA Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerWho this might be right forROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer Xuanzhu Biopharmaceutical Co., Ltd. 114
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401What this trial is testingStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsWho this might be right forSolid TumorsCNS Tumors Hoffmann-La Roche 69
Testing effectiveness (Phase 2)UnknownNCT03608007What this trial is testingX-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementWho this might be right forLung CancerROS1 Gene Rearrangement Betta Pharmaceuticals Co., Ltd. 69
Early research (Phase 1)Active Not RecruitingNCT05681780What this trial is testingClinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCWho this might be right forNon Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer H. Lee Moffitt Cancer Center and Research Institute 13
Early research (Phase 1)Active Not RecruitingNCT02321501What this trial is testingCeritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerWho this might be right forALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT04042558What this trial is testingA Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesWho this might be right forNSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more Centre Francois Baclesse 150
Testing effectiveness (Phase 2)Looking for participantsNCT04084717What this trial is testingStudy of Crizotinib for ROS1 and MET Activated Lung CancerWho this might be right forNon-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene Rearrangement+2 more University Health Network, Toronto 50
Testing effectiveness (Phase 2)WithdrawnNCT03164694What this trial is testingAPatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCWho this might be right forLung Cancer Sun Yat-sen University